PMC4754989_01
Baseline brain MRI images showing initial primary mucosal melanoma lesion. Primary melanoma centered in the sphenoethmoidal sinuses. Representative sagittal and coronal T1 images are displayed. The upper boxes correspond to the initial MRI, while the lower boxes reflect post-treatment images. Yellow arrows denote approximate tumor boundaries
40425_2016_114_Fig1_HTML.jpg
PMC4754989_01_40425_2016_114_Fig1_HTML.jpg
Fig1
The upper boxes in Fig. 1 show representative images of the patient's baseline MRI. A follow-up MRI of his brain to reassess the primary tumor mass in the paranasal sinuses correlated with the response noted in the PET/CT and representative images compared to the original MRI are available in Fig. 1.
Baseline (left column) and post-pembrolizumab (right column) therapy representative PET/CT images. Side-by-side comparative images of PET/CT scan at baseline and after the first four doses of pembrolizumab. Yellow arrows denote sites of active or previously identified melanoma deposits. (1 and 2) Primary sphenoethmoidal mass showing a CR after treatment. (3 and 4) CR in a left hepatic lobe liver metastasis. (5 and 6) CR in two intra-abdominal metastatic implants and in a vertebral metastasis
40425_2016_114_Fig2_HTML.jpg
PMC4754989_01_40425_2016_114_Fig2_HTML.jpg
Fig2
Repeat PET/CT was performed after four doses of pembrolizumab and representative images are shown in Fig. 2 compared to the baseline PET/CT scan.